LPAAW — Launch One Acquisition Corp.
—
Nasdaq ·
Financials ·
Diversified Financial Services ·
CIK 2015502 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -467,775 | 1,700,072 | 248,069,099 | 266,001 | 12,479,635 |
| Dec 2025 | 0 | — | -277,941 | 2,088,681 | 245,630,529 | 30,146 | 11,741,137 |
| Sep 2025 | 0 | — | -517,261 | 2,011,042 | 243,472,003 | 97,652 | 11,671,292 |
| Jun 2025 | 0 | — | -637,837 | 1,922,018 | 241,152,118 | 263,740 | 11,362,449 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-902,922
Investing CF
$0
Financing CF
$500,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-12,028,308
Inventory
—
Receivables
$28,590
ST Investments
—
EBIT TTM
$-1,900,814
Pretax Income TTM
$7,721,813
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,611,081 | 8,309,154 | 245,630,529 | 11,741,137 | — | -820,192 |
| Dec 2024 | 0 | -400,002 | 5,129,519 | 236,639,418 | 11,059,180 | — | -472,305 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HASI | HA Sustainable Infrastructure Capital, Inc. | $4.84B | $37.87 | — |
| DMII | Drugs Made In America Acquisition II Corp. | $644.01M | $10.11 | — |
| EVAC | EQV Ventures Acquisition Corp. II | $480.98M | $10.24 | — |
| BCSS | Bain Capital GSS Investment Corp. | $479.32M | $10.22 | — |
| CEPF | Cantor Equity Partners IV, Inc. | $477.82M | $10.41 | — |
News headlines (Yahoo Finance, 1h cache)
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
2025-10-15 11:30 · Yahoo
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
2025-09-18 11:30 · Yahoo
Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers
2025-08-27 11:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.